Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 76 Degree of Operating Leverage is -28.26 as of Jun. 2026. GuruFocus rates CSBTF with a GF Score™ of 76/100 and a GF Value™ of $43.61 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 790 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 94.56% on this metric.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
Kuros Biosciences's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was -28.26. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for Kuros Biosciences's Degree of Operating Leverage or its related term are showing as below:
CSBTF's Degree of Operating Leverage is ranked better than 94.56% of 790
companies
in the Medical Devices & Instruments industry
Industry Median: 0.46
vs CSBTF: -28.26
Kuros Biosciences (OTCPK:CSBTF) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Kuros Biosciences Degree of Operating Leverage Related Terms
Kuros Biosciences Degree of Operating Leverage Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Degree of Operating Leverage Chart
CSBTF vs ABT, SYK, MDT: Degree of Operating Leverage Comparison
For the Medical Devices subindustry, Kuros Biosciences's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Degree of Operating Leverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of -28.26 mean?
Kuros Biosciences (CSBTF) has a Degree of Operating Leverage of -28.26 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #43 out of 790 companies in the Medical Devices & Instruments industry, placing it in the top 5.4%.
Is Kuros Biosciences' Degree of Operating Leverage too high?
Kuros Biosciences' current Degree of Operating Leverage is -28.26. Based on the distribution chart, Kuros Biosciences ranks #43 out of 790 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Degree of Operating Leverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #43 out of 790 companies for Degree of Operating Leverage. This places Kuros Biosciences in the top 5% of its industry — outperforming the majority of peers. The industry median Degree of Operating Leverage is 0.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Medical Devices & Instruments company?
The median Degree of Operating Leverage among Medical Devices & Instruments companies is 0.46, based on 790 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Degree of Operating Leverage is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Degree of Operating Leverage is -28.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $43.61, compared to a current price of $26.99 — trading 38.1% below its estimated fair value. The current Degree of Operating Leverage is -28.26. Kuros Biosciences' overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Degree of Operating Leverage is -28.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $26.99 is trading 38.1% below its estimated GF Value™ of $43.61.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Degree of Operating Leverage: -28.26
GF Value™: $43.61 vs. price of $26.99 (38.1% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
76GF Score
Get the complete analysis for CSBTF
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
